Sana Biotechnology

Update in progress

SANA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Sana Biotechnology, Inc. focuses on engineered cells as medicines in the United States, developing ex vivo and in vivo cell engineering platforms for unmet needs in type 1 diabetes, B cell autoimmune diseases, and oncology. Pipeline includes UP421, a HIP-modified allogeneic islet product in phase 1; SC451, HIP-modified stem cell–derived islet therapy in preclinical; SG293/SG299, CD8-targeted fusosomes for B cell cancers and autoimmunity. Partners include Beam for Cas12b editing, Harvard for hypoimmune tech, and Mayo Clinic for SC451. Formerly FD Therapeutics; renamed 2018; Seattle.

Company score

Sentiment: -0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive